Skip to main content
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2022 Jan 20;2:100066. doi: 10.1016/j.nerep.2022.100066

Post-COVID-19 acute disseminated encephalomyelitis: Case report and review of the literature

Masoud Etemadifar a, Amir Reza Mansouri b, Hosein Nouri b,c, Nahad Sedaghat b,c, Mehri Salari d, Milad Maghsoudi b, Narges Heydari b,
PMCID: PMC8772132

Abstract

Background

Our understanding of the spectrum of neurological manifestations associated with COVID-19 keeps evolving. Reports of life-threatening neurological complications, such as acute disseminated encephalomyelitis (ADEM), are alarmingly growing in number.

Case presentation

We report a 42 years old previously healthy man who presented with left visual loss and cognition deterioration, manifesting at least ten days after infection with SARS-CoV-2. Serological work-up for potential immunological markers (i.e., antibodies against aquaporin-4 and myelin oligodendrocyte glycoprotein) were negative. Magnetic resonance imaging revealed multiple bilateral and asymmetrical lesions in the brainstem, cortical, juxtacortical, and periventricular regions, with surrounding edema. Post-contrast sequences demonstrated punctate, ring, and open ring enhancement patterns. Methylprednisolone pulse therapy was initiated for the patient, and he was placed on rituximab. After one month, his clinical symptoms had resolved, and his cognitive function was normal.

Conclusions

We conducted an extensive literature search, and COVID-19-associated ADEM cases reported thus far were identified and reviewed. ADEM often occurs in a post-infectious fashion; however, it is unclear how SARS-CoV-2 infection can trigger such rapidly progressive episodes of encephalopathy and demyelination. Nevertheless, considering the alarming number of cases of ADEM developing after SARS-CoV-2 infection, neurologists should consider this severe phenotype of COVID-19 neurological complication in mind, enabling prompt therapeutic interventions to be made.

Keywords: COVID-19, SARS-CoV-2, Post-infectious, Acute disseminated encephalomyelitis, ADEM

Introduction

With the ongoing pandemic of Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, significant concerns were raised regarding the spectrum of neurological manifestations associated with this infection. A wide variety of such complications can occur in COVID-19 patients, with various pathologies and degrees of severity, due to either direct or indirect involvement of the central nervous system (CNS) (Al-Sarraj et al., 2021). There are numerous reports of CNS immune-mediated conditions; the underlying pathogenesis is not clear yet.

Several cases of acute disseminated encephalomyelitis (ADEM; an immune-mediated demyelinating disorder of the CNS) after infection with SARS-CoV-2 have been reported (reviewed in Table 1 ). ADEM is more frequently observed in children, especially after infection and reports have shown that ADEM might be associated with vaccination (Baxter et al., 2016). It is generally regarded as monophasic, i.e., no new episode may occur three months after the first episode in most cases (Pohl et al., 2016). The clinical profile usually includes an initial prodromal phase, where fever, nausea, vomiting, headache, and weakness may be present, followed by acute-onset, rapidly progressive encephalopathy and multifocal neurological symptoms. A wide variety of neurological deficits (e.g., pyramidal signs, ataxia, hemiparesis, cranial nerves involvement, and seizures) can be manifested, determined mainly by the localization of lesions (Pohl et al., 2016, Tenembaum et al., 2007). Multiple large bilateral lesions are typically visualized on magnetic resonance imaging (MRI) studies as T2 and fluid-attenuated inversion recovery (FLAIR) hyperintensities; they are asymmetric in shape and location and have ill-defined margins (Pohl et al., 2016, Tenembaum et al., 2002). With variable clinical and radiologic features and no specific biomarker, diagnosis of ADEM requires exclusion of other probable diagnoses. It is worth mentioning that autoimmune encephalitis(AE) is also associated with Covid-19 and has similarities in pathophysiology and clinical manifestations, which therefore can cause diagnostic challenges. Although ADEM and AE have similar presentations, symptoms develop more rapidly in ADEM (McGetrick et al., 2021).

Table 1.

Demographic, clinical, radiological of cases with acute disseminated encephalomyelitis associated with COVID-19, along with their treatments and outcomes.

Case Age/ Sex publication date country of study ADEM symptoms MRI finding Treatment Outcome
1 Novi et al. (2020) 64/F September 2020 Italy Severe visual lossSensory deficitHeadacheHyperreflexiaBabinski signRight abdominal sensory levelIrritability Multiple T1 post-Gd enhancing lesions of the brain, associated with a single spinal cord lesion at the T8 level and with bilateral optic nerve enhancement High-dose steroidsIVIG Significant improvement in visual symptomsReduced number of Gd-enhancing lesions in follow-up brainMRI
2 Virhammar et al. (2020) ANE 55/F September 2020 Sweden StuporMultifocal myoclonus Symmetrical FLAIR hyperintensities signal symmetrically in central thalami, subinsular regions and thalami, medial temporal lobes, and brain stem, consistent with ANE AcyclovirIVIGPlasma exchange The patient clinically improved
3 Dixon et al. (2020) ANE 59/F September 2020 United Kingdom Seizure (GTCS)Reduced level of consciousnessUnreactive left pupil Brain stem swelling, symmetrical hemorrhagic lesions in the brain stem, amygdalae, putamina, and thalamic nuclei High-dose steroidsLevetiracetamAcyclovirCeftriaxoneAmoxicillinClarithromycin Died
4 Parsons et al. (2020) 51/F May 2020 USA UnresponsivenessDepressed deep tendon reflexesMute plantar responsesFlaccid muscle tone Small Gd-enhancing lesion in the left frontal lobe at the gray-white interface and FLAIR hyperintensities in the deep hemispheric, periventricular and juxtacortical white matter High-dose steroids IVIG Fully oriented
5 de Miranda Henriques-Souza et al. (2021) 12/F October 2020 Brazil Flaccid tetraplegiaDeep areflexiaTingling and numbness in the inferior limbs Extensive bilateral and symmetric restricted diffusion involving the subcortical and deep white matterFocal hyperintense T2 FLAIR lesion in the splenium of the corpus callosum with restricted diffusion High-dose steroids Partial improvement
6 Langley et al. (2020) 53/M November 2020 United Kingdom HypotoniaAgitation Bilateral multiple hyperintense lesions within the subcortical and deep white matter of the frontoparietal lobesSmall amount of IVH within the occipital horns of the lateral ventricles High-dose steroids The patient clinically improved
7 Lopes et al. (2020) 59/F October2020 Brazil Reduced level of consciousnessAsymmetric flexor motor responsesHyporeflexia Multiple bilateral focal areas of signal abnormalities in the cerebral and cerebellar white matter HydroxychloroquineBroad-spectrum antibiotics Died
8 Lopes et al. (2020) 41/M October2020 Brazil Reduced level of consciousnessFour-limb weaknessBlunted affectPoor verbal interaction Focal lesions located in the centrum semiovale, bilaterally, right thalamus, globus pallidus bilaterally and anterior limb of internal capsule, characterized by hyperintensity on axial FLAIR images, high signal on DWI and apparent diffusion coefficient, representing diffusion facilitation Not reported Fully alert and cooperative patient, with mild attentional and executive dysfunction
9 Hussein et al. (2020) 55/F September 2020 USA Reduced level of consciousnessSeizureGeneralized weakness Mild asymmetric FLAIR hyperintensities in the left>right cerebral cortex, thalami, the left sub splenial region,the left subcortical optic radiations and the mid pons LevetiracetamLacosamideTopiramateIVIGHigh-dose steroidsPlasmapheresis The patient clinically and electrographically improved
10 Umapathi et al. (2020) 59/M September 2020 Singapore DrowsyRoving eye movementsTransient ocular flutter Multiple discrete hyperintense foci in the periventricular and deep white matter bilaterally, with foci in the temporal region, subcortical white matter as well as the forceps minor Convalescent plasmaIVIG He was able to open eyes spontaneously, track visually and smile meaningfully. However, he had no coherent volitionalmotor and verbal response to the environment
11 Reichard et al. (2020) 71/M May 2020 USA Not reported Not reported High-dose steroidsVasopressor Died
12 Zhang et al. (2020) 40/F April 2020 USA DysphagiaDysarthriaEncephalopathy Extensive patchy areas of abnormal signal involving bilateral frontoparietal white matter, anterior temporal lobes, basal ganglia, external capsules, and thalami HydroxychloroquineCeftriaxoneIVIG The patient clinically improved
13 Shahmirzaei and Naser Moghadasi (2021) 30/M January 2021 Iran AtaxiaConfusion Multiple enhanced lesion High-dose steroidsRituximab The patient clinically improved
14 McCuddy et al. (2020) 37/F 2020 USA Plegic in legs bilaterallySymmetric weakness in the upper extremity Multiple T2 hyperintense lesions with restricted diffusion involving the corpus callosum, bilateral cerebral white matter, right pons and in the bilateral ventral medulla DecadronHydroxychloroquine ZincConvalescent plasma Partial improvement
15 McCuddy et al. (2020) 56/M 2020 USA Unresponsive,Eyes with leftward deviation,No spontaneous limb movements, Reflexes reduced Several T2 hyperintense lesions, many with restricted diffusion, in cerebral white matterNo hemorrhage SolumedrolIVIGConvalescent plasma Clinically, not opening eyes, unresponsiveRemains on ventilator with tracheostomy
16 McCuddy et al. (2020) 70/F 2020 USA severe diffuse weaknessUnresponsive to verbal stimuliWithdraws to pain slightly Several T2 hyperintense lesions, most with restricted diffusion, in deep cerebral white matterMinimum enhancement and no hemorrhage SolumedrolIVIGConvalescent plasma Spontaneously opens eyesdecorticate posturing in upper extremityWithdraws lower extremity to stimuli Weaning from the ventilator
17 AHL Handa et al. (2020) 33/M September 2020 India Four-limb weaknessSeizure (GTCS)DTR: absentBabinski sign Symmetrical FLAIR hyperintensities involving bilateral subcortical fronto-parietal lobes, splenium of corpus callosum, medulla and visualised cervical cord with petechial haemorrhages and evidence of diffusion restriction involving splenium of corpus callosum AcyclovirCeftriaxoneLacosamideHigh-dose steroids Died
18 Manzo et al. (2021) 6/M May 2021 Italy Seizure (GTCS) T2-FLAIR hyperintense lesions in the right cerebellar hemisphere, cortical-subcortical cuneus gyrus of the right parietal lobe, left side of the corpus callosum and corona radiata, cortical-subcortical inferior left parietal gyrus High-dose steroids The patient clinically improved
19 AHL Varadan et al. (2021) 46/M February 2021 India HeadacheReduced level of consciousnessLoss of power in the left limbsLeft facial nerve palsy Hyperintense white matter lesions in bilateral frontal, parietal lobes, left thalamus, left cerebral peduncle, and medulla T2W and FLAIR, hypointense onT1WPre and postcontrast of lesions show patchy, rim enhancement with central nonenhancingcomponent High-dose steroids Died
20 McLendon et al. (2021) 17-month /F March 2021 USA IrritabilityWeakness of upper extremitiesAtaxiaNeck stiffnessBrudzinski's sign Revealed multifocal hyperintense FLAIR signals in bilateral subcortical and periventricular whitematter without contrast enhancement IVIGHigh-dose steroids The patient clinically improved
21 ANHLE Alqahtani et al. (2021) 59/M June 2021 Saudi Arabia Reduced level of consciousnessAbsence of some brainstem reflexes Extensive brain abnormality predominantly involving the deep white matter with micro haemorrhages Health guidelines of Saudi Ministry Died
22 ANHLE Alqahtani et al. (2021) 47/F June 2021 Saudi Arabia Reduced level of consciousnessBlurred visionAbnormal movement of the right upper limb and left lower limb Diffuse petechial hemorrhages especially in the basal ganglia that is compatible with diffuse necrotizing leukoencephalitis Not reported Coma
23 Kumar et al. (2020) 35/F September 2020 USA Gait instabilitySymmetric distal neuropathyReduced level of consciousness Hemispheric white matter signal in juxtacortical regions extending to anteromedial temporal lobesSymmetric periventricular white matter FLAIR hyperintensities involving bilateral cerebral peduncles with mild diffusion restriction High-dose steroidsIVIGplasma exchange She had not improved, and was transferred to a long term care facility
24 AHL Haqiqi et al. (2021) 56/F January 2021 United Kingdom Reduced level of consciousness Extensive symmetrical FLAIR abnormal signal throughout the white matter bilaterally with hemorrhage compatible with haemorrhagic leukoencephalitis AnticoagulationAntihypertensive The patient neurological condition hasremained stableHe discharged to a neurorehabilitation center.
25 AHL Yong et al. (2020) 61/M July 2020 Singapore Flaccid tetraplegiaAbsent plantar reflexes Asymmetrical, multifocal lesions in the subcortical white matter of bilateral cerebral hemispheres, cortex, Bilateral thalami, and cerebellar hemispheres, petechial hemorrhage and vasogenic edema within the lesions10 mm rightward midline shift RemdesivirPlasma exchangeIVIG The patient clinically improved
26 Abdi et al. (2020) 58/M June 2020 Iran Reduced level of consciousnessInability to walkStatus epilepticus Diffuse confluent white matter hyperintensity on FLAIR, particularly at the left-side without prominent enhancement on T1 High-dose steroids Died
27 Walker et al. (2021) 51/F April 2021 USA Increased seizure activityIncontinenceAphasia Not reported Remdesivir Died
28 Walker et al. (2021) 64/M April 2021 USA Nonresponsive with a fixed and dilated right pupil Not reported RemdesivirConvalescent plasma Corticosteroids Died
29 Delamarre et al. (2020) 51/M September 2020 France Unresponsive comaPyramidal syndromeRight-sidedsixth nerve palsyNo cornealreflex Diffuse hyperintense lesions on FLAIR images without Gd-enhanced lesions High-dose steroids IVIG The patient showedcomplete motor recovery
30 Karapanayiotides et al. (2020) 57/M October 2020 Greece Reduced level of consciousnessHyperreflexiaBlunted vestibulo-ocular reflexes Concentric demyelination pattern AzithromycinHydroxychloroquineRitonavir Interleukin-1 antagonist The patient recovered, and 1 month later, he only had moderate tetraparesis
31 Poyiadji et al. (2020) ANE ?/F March 2020 USA Altered mental status hemorrhagic rim enhancing lesions within the bilateral thalami, medial temporal lobes, and subinsular regions IVIG Not reported

Abbreviations: Gd, Gadolinium; ANE, Acute necrotizing encephalopathy; AHL, Acute hemorrhagic leukoencephalitis/leukoencephalomyelitis; ANHLE, Acute necrotic hemorrhagic leukoencephalitis; GTCS, Generalized tonic-clonic seizure; IVIG, intravenous immunoglobulin G; IVH, Intraventricular hemorrhage; DWI, Diffusion weighted imaging.

We describe the case of an adult patient who developed an ADEM episode shortly after he was infected with SARS-CoV-2. We conducted an extensive search of relevant literature and summarized the existing data on post-infectious ADEM in the context of COVID-19.

Case presentation

In early January 2021, a previously healthy 42-year-old man presented with visual loss in the left eye, bilateral ptosis, drowsiness, and declined cognition from three days before admission. He had been quarantined in a non-healthcare setting from 10 days before the onset of his neurological symptoms for a history of low-grade fever, dyspnea, cough, and myalgia. Nasopharyngeal swab polymerase chain reaction (PCR) was positive for SARS-CoV-2 and negative for influenza H1N1.

Upon physical examination, he was not febrile, and his vital signs were stable. The patient was lethargic and irritable. His-left visual acuity was 20/50; reflex afferent papillary defect in the corresponding eye was 3+. Bilateral ptosis, more prominent in the left side, was detected. There was mild paraparesis in the lower extremities (4/5). Sensory and cerebellar functions, deep tendon reflexes, and plantar reflexes were normal. Results from optical coherence tomography (OCT) performed by an ophthalmologist were normal.

Electrolytes, white blood cells, hemoglobin, C-reactive protein, transaminases, Serum creatinine levels were within the normal range, as were his TSH, T3, and FT4 levels.

Additional tests showed negative neuromyelitis Optica antibody (NMO-IgG) and negative myelin oligodendrocyte glycoprotein antibody (MOG-IgG) results.

Brain magnetic resonance imaging (MRI) sequences were obtained. Multiple bilateral and asymmetrical lesions were observed in the brainstem, cortical, juxtacortical, and periventricular regions, appearing as hyperintensities with surrounding edema on T2-weighted and Fluid-attenuated inversion recovery (FLAIR) images. Post-contrast T1-weighted sequences revealed punctate, ring, and open ring enhancement patterns. Electroencephalogram (EEG) showed generalized slowing with no epileptiform discharge.

The patient underwent methylprednisolone pulse therapy for five days (1 g/day), followed by two doses of rituximab infusion (1 g/infusion; with a two-week interval). After one month, the patient's clinical symptoms resolved, visual acuity was normal (10/10), ptosis and mental status evaluation were also normal.

Discussion

Adding to the growing body of evidence, we reported a case of post-COVID-19 ADEM with manifestations of cognitive deficits and visual loss in a 42-year-old man. Although this demyelinating disorder of the CNS tends to occur after infections, an exact, causal relationship between infections and ADEM is yet to be determined (Pohl et al., 2016). The absence of NMO-IgG and MOG-IgG excluded the probability of Neuromyelitis optica spectrum disorder and MOG-associated Disease, resulting in ADEM diagnosis. Unlike the predominance of ADEM occurrence in children, our patient, similar to most reported cases of COVID-19-associated ADEM, was a middle-aged individual.

Our extensive search of the existing literature on COVID-19 and associated ADEM yielded 31 cases; data extracted from those cases are presented in Table 1. As interpreted from Table 1, there was no gender predominance among the cases (16 females, 15 males). Most patients (90.3%; 28/31) were adults with an average age of 52.3 years. Only a few patients had severe COVID-19-associated symptoms and required intensive care. 55.8% (17/31) had reduced levels of consciousness and a decreased GCS. Muscle weakness or decreased muscle tone was observed in 35.4% (11/31); 4 patients (Novi et al., 2020, Langley et al., 2020, Shahmirzaei and Naser Moghadasi, 2021, McCuddy et al., 2020) developed seizures, and the frequency of seizures was increased in one patient who had seizures before COVID-19 infection (Yong et al., 2020). In addition to our case, visual impairments were reported in two patients (Tenembaum et al., 2002, Varadan et al., 2021). MRI findings of these patients showed multiple lesions in various regions of the CNS Fig. 1 .

Fig. 1.

Fig. 1

Fluid-attenuated inversion recovery images (a–f) of the brain showing multiple high-signal lesion in the brainstem, cortical, juxtacortical, and periventricular areas. Post-contrast T1-weighted sequences (g–l) showing enhanced lesion as target sign with low-signal dot in the center of lesion.

Different outcomes ensued with the treatments applied in the reported cases. In 58% (18/31) of cases, symptoms improvement and MRI lesions reduction were achieved. Unfortunately, 25% died. Others showed no progression of their symptoms. One patient's treatment outcome was not mentioned (Karapanayiotides et al., 2020). The neurological manifestations associated with ADEM after the COVID-19 course can significantly increase morbidity and mortality and can multiple the hospitalization time. Although corticosteroids can be beneficial in the resolution of symptoms in ADEM patients, prescription of corticosteroids should be done with caution as it can increase the risk of increased viral replication (McCuddy et al., 2020).

It is notable that while COVID-19-associated ADEM patients predominantly presented with reduced level of consciousness and muscle weakness, a review shows that the most common symptoms in patients with COVID-19-associated autoimmune encephalitis are altered mental status, seizures and ataxia (Payus et al., 2021).

In conclusion, given the significant number of ADEM cases associated with SARS-CoV-2 infection reviewed above, neurologists should bear in mind severe neurological complications that might occur after an unfortunate COVID-19 infection and promptly take action to prevent further potential damages.

References

  1. Al-Sarraj S., Troakes C., Hanley B., Osborn M., Richardson M.P., Hotopf M., Bullmore E., Everall I.P. Invited review: the spectrum of neuropathology in COVID-19. Neuropathol. Appl. Neurobiol. 2021;47(1):3–16. doi: 10.1111/nan.12667. [DOI] [PubMed] [Google Scholar]
  2. Baxter R., Lewis E., Goddard K., Fireman B., Bakshi N., DeStefano F., Gee J., Tseng H.F., Naleway A.L., Klein N.P. Acute demyelinating events following vaccines: a case-centered analysis. Clin. Infect. Dis. 2016;63(11):1456–1462. doi: 10.1093/cid/ciw607. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Pohl D., Alper G., Van Haren K., Kornberg A.J., Lucchinetti C.F., Tenembaum S., Belman A.L. Acute disseminated encephalomyelitis: updates on an inflammatory CNS syndrome. Neurology. 2016;87(9 Suppl 2):S38–S45. doi: 10.1212/WNL.0000000000002825. [DOI] [PubMed] [Google Scholar]
  4. Tenembaum S., Chitnis T., Ness J., Hahn J.S. International pediatric MS study group. Acute disseminated encephalomyelitis. Neurology. 2007;68(16 Suppl 2):S23–S36. doi: 10.1212/01.wnl.0000259404.51352.7f. [DOI] [PubMed] [Google Scholar]
  5. Tenembaum S., Chamoles N., Fejerman N. Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology. 2002;59(8):1224–1231. doi: 10.1212/wnl.59.8.1224. [DOI] [PubMed] [Google Scholar]
  6. McGetrick M.E., Varughese N.A., Miles D.K., Wang C.X., McCreary M., Monson N.L., Greenberg B.M. Clinical features, treatment strategies, and outcomes in hospitalized children with immune-mediated encephalopathies. Pediatr. Neurol. 2021;116:20–26. doi: 10.1016/j.pediatrneurol.2020.11.014. [DOI] [PubMed] [Google Scholar]
  7. Novi G., Rossi T., Pedemonte E., Saitta L., Rolla C., Roccatagliata L., Inglese M., Farinini D. Acute disseminated encephalomyelitis after SARS-CoV-2 infection. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(5):e797. doi: 10.1212/NXI.0000000000000797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Virhammar J., Kumlien E., Fallmar D., Frithiof R., Jackmann S., Skold M.K., et al. Acute necrotizing encephalopathy with SARS-CoV-2 RNA confirmed in cerebrospinal fluid. Neurology. 2020;95(10):445–449. doi: 10.1212/WNL.0000000000010250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dixon L., Varley J., Gontsarova A., Mallon D., Tona F., Muir D., et al. COVID-19-related acute necrotizing encephalopathy with brain stem involvement in a patient with aplastic anemia. Neurol. Neuroimmunol. Neuroinflamm. 2020;7(5) doi: 10.1212/NXI.0000000000000789. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Parsons T., Banks S., Bae C., Gelber J., Alahmadi H., Tichauer M. COVID-19-associated acute disseminated encephalomyelitis (ADEM) J. Neurol. 2020;267(10):2799–2802. doi: 10.1007/s00415-020-09951-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. de Miranda Henriques-Souza A.M., de Melo A., de Aguiar Coelho Silva Madeiro B., Freitas L.F., Sampaio Rocha-Filho P.A., Goncalves F.G. Acute disseminated encephalomyelitis in a COVID-19 pediatric patient. Neuroradiology. 2021;63(1):141–145. doi: 10.1007/s00234-020-02571-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Langley L., Zeicu C., Whitton L., Pauls M. Acute disseminated encephalomyelitis (ADEM) associated with COVID-19. BMJ Case Rep. 2020;13(12) doi: 10.1136/bcr-2020-239597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lopes C.C.B., Brucki S.M.D., Passos Neto C.E.B., Corazza L.A., Baima J.P.S., Fiorentino M.D., et al. Acute disseminated encephalomyelitis in COVID-19: presentation of two cases and review of the literature. Arq. Neuropsiquiatr. 2020;78(12):805–810. doi: 10.1590/0004-282X20200186. [DOI] [PubMed] [Google Scholar]
  14. Hussein O., Abd Elazim A., Torbey M.T. Covid-19 systemic infection exacerbates pre-existing acute disseminated encephalomyelitis (ADEM) J. Neuroimmunol. 2020;349 doi: 10.1016/j.jneuroim.2020.577405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Umapathi T., Quek W.M.J., Yen J.M., Khin H.S.W., Mah Y.Y., Chan C.Y.J., et al. Encephalopathy in COVID-19 patients; viral, parainfectious, or both?. eNeurologicalSci. 2020;21:100275. [DOI] [PMC free article] [PubMed]
  16. Reichard R.R., Kashani K.B., Boire N.A., Constantopoulos E., Guo Y., Lucchinetti C.F. Neuropathology of COVID-19: a spectrum of vascular and acute disseminated encephalomyelitis (ADEM)-like pathology. Acta Neuropathol. 2020;140(1):1–6. doi: 10.1007/s00401-020-02166-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Zhang T., Rodricks M.B., Hirsh E. COVID-19-associated acute disseminated encephalomyelitis-a case report. medRxiv. 2020;16 04. [Google Scholar]
  18. Shahmirzaei S., Naser Moghadasi A. Association of COVID-19 and Acute Disseminated Encephalomyelitis (ADEM) in the absence of pulmonary involvement. Autoimmun. Rev. 2021;20(3) doi: 10.1016/j.autrev.2021.102753. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. McCuddy M., Kelkar P., Zhao Y., Wicklund D. Acute demyelinating encephalomyelitis (ADEM) in COVID-19 infection: a case series. Neurol. India. 2020;68(5):1192–1195. doi: 10.4103/0028-3886.299174. [DOI] [PubMed] [Google Scholar]
  20. Handa R., Nanda S., Prasad A., Anand R., Zutshi D., Dass S.K., et al. Covid-19-associated acute haemorrhagic leukoencephalomyelitis. Neurol. Sci. 2020;41(11):3023–3026. doi: 10.1007/s10072-020-04703-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Manzo M.L., Galati C., Gallo C., Santangelo G., Marino A., Guccione F., et al. ADEM post-Sars-CoV-2 infection in a pediatric patient with Fisher-Evans syndrome. Neurol. Sci. 2021 doi: 10.1007/s10072-021-05311-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Varadan B., Shankar A., Rajakumar A., Subramanian S., Sathya A.C., Hakeem A.R., et al. Acute hemorrhagic leukoencephalitis in a COVID-19 patient-a case report with literature review. Neuroradiology. 2021;63(5):653–661. doi: 10.1007/s00234-021-02667-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. McLendon L.A., Rao C.K., Da Hora C.C., Islamovic F., Galan F.N. Post-COVID-19 acute disseminated encephalomyelitis in a 17-month-old. Pediatrics. 2021;147(6) doi: 10.1542/peds.2020-049678. [DOI] [PubMed] [Google Scholar]
  24. Alqahtani A., Alaklabi A., Kristjansson S., Alharthi H., Aldhilan S., Alam H. Acute Necrotic Hemorrhagic Leukoencephalitis related to COVID-19: a report of two cases. Radiol. Case Rep. 2021 doi: 10.1016/j.radcr.2021.05.072. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Kumar A., Olivera A., Mueller N., Howard J., Lewis A. Delayed SARS-COV-2 leukoencephalopathy without severe hypoxia. J. Neurol. Sci. 2020;418 doi: 10.1016/j.jns.2020.117146. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Haqiqi A., Samuels T.L., Lamb F.J., Moharrum T., Myers AE. Acute haemorrhagic leukoencephalitis (Hurst disease) in severe COVID- 19 infection. Brain Behav. Immun. Health. 2021;12 doi: 10.1016/j.bbih.2021.100208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Yong M.H., Chan Y.F.Z., Liu J., Sanamandra S.K., Kheok S.W., Lim K.C., et al. A rare case of acute hemorrhagic leukoencephalitis in a COVID-19 patient. J Neurol Sci. 2020;416 doi: 10.1016/j.jns.2020.117035. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Abdi S., Ghorbani A., Fatehi F. The association of SARS-CoV-2 infection and acute disseminated encephalomyelitis without prominent clinical pulmonary symptoms. J. Neurol. Sci. 2020;416 doi: 10.1016/j.jns.2020.117001. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Walker J.M., Gilbert A.R., Bieniek K.F., Richardson TE. COVID-19 patients with CNS complications and neuropathologic features of acute disseminated encephalomyelitis and acute hemorrhagic leukoencephalopathy. J. Neuropathol. Exp. Neurol. 2021;80(6):628–631. doi: 10.1093/jnen/nlab036. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Delamarre L., Gollion C., Grouteau G., Rousset D., Jimena G., Roustan J., et al. COVID-19-associated acute necrotising encephalopathy successfully treated with steroids and polyvalent immunoglobulin with unusual IgG targeting the cerebral fibre network. J. Neurol. Neurosurg. Psychiatry. 2020;91(9):1004–1006. doi: 10.1136/jnnp-2020-323678. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Karapanayiotides T., Geka E., Prassopoulos P., Koutroulou I., Kollaras P., Kiourtzieva E., et al. Concentric demyelination pattern in COVID-19-associated acute haemorrhagic leukoencephalitis: a lurking catastrophe? Brain. 2020;143(12):e100. doi: 10.1093/brain/awaa375. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Poyiadji N., Shahin G., Noujaim D., Stone M., Patel S., Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: imaging features. Radiology. 2020;296(2):E119–EE20. doi: 10.1148/radiol.2020201187. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Payus A.O., Jeffree M.S., Ohn M.H., Tan H.J., Ibrahim A., Chia Y.K., Raymond AA. Immune-mediated neurological syndrome in SARS-CoV-2 infection: a review of literature on autoimmune encephalitis in COVID-19. Neurol. Sci. 2021:1–15. doi: 10.1007/s10072-021-05785-z. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Neuroimmunology Reports are provided here courtesy of Elsevier

RESOURCES